

EIA results in External Quality Assessments (EQA) Q3-Q4 2025

Content

STATISTICS

Average EIA success rate in EQA in Q3-Q4 2025.....	5
Average success rate of EIA parameters in EQA in Q3-Q4 2025.....	5

INFECTIOUS DISEASES

Bordetella.....	8
Borrelia	9
Chlamydia.....	11
Coronavirus (COVID-19).....	17
Cytomegalovirus (CMV).....	19
Epstein-Barr virus (EBV).....	21
Helicobacter.....	26
Herpes simplex virus (HSV).....	28
Measles	31
Mumps.....	32
Mycoplasma.....	33
Parvovirus B19	35
Rubella	36
Tick-Borne Encephalitis Virus (TBEV).....	37
Tetanus.....	38
Toxocara.....	39
Toxoplasma	40
Treponema	42
Varicella zoster virus (VZV).....	43
Yersinia.....	44

IMMUNOLOGY & AUTOIMMUNE DISEASES

Antibodies to <i>Saccharomyces cerevisiae</i> (ASCA)	46
Cyclic citrullinated peptides (CCP)	47
Deamidated gliadin (Gliadin DA)	48
Double-stranded DNA (dsDNA)	49
Jo-1.....	50
Scl-70	52
Transglutaminase (TA).....	53

Statistics

Average EIA success rate in EQA in Q3-Q4 2025

<u>CAP</u>	<u>INSTAND</u>	<u>LABQUALITY</u>	<u>SEKK</u>	<u>SZÚ</u>
100.0%	97.4%	97.6%	100.0%	98.5%

Average success rate of EIA parameters in EQA in Q3-Q4 2025

INFECTIOUS DISEASES

<u>Parameter</u>	<u>CAP</u>	<u>INSTAND</u>	<u>LABQUALITY</u>	<u>SEKK</u>	<u>SZÚ</u>
Bordetella		100.0%	100.0%		
Borrelia		100.0%	100.0%		100.0%
Chlamydia		100.0%	88.9%		93.3%
Coronavirus (COVID-19)		100.0%			
Cytomegalovirus (CMV)	100.0%	100.0%	100.0%		
Epstein-Barr virus (EBV)	100.0%	100.0%	95.8%		
Helicobacter	100.0%	100.0%	100.0%		100.0%
Herpes simplex virus (HSV)	100.0%	91.7%	88.9%		91.7%
Measles		100.0%			
Mumps		100.0%			
Mycoplasma	100.0%	100.0%	100.0%		
Parvovirus B19		100.0%			
Rubella	100.0%	100.0%			100.0%
Tick-Borne Encephalitis Virus (TBEV)		100.0%			
Tetanus		100.0%			

<u>Parameter</u>	<u>CAP</u>	<u>INSTAND</u>	<u>LABQUALITY</u>	<u>SEKK</u>	<u>SZÚ</u>
Toxocara*					100.0%
Toxoplasma	100.0%		100.0%		100.0%
Treponema					100.0%
Varicella zoster virus (VZV)	100.0%	100.0%			100.0%

IMMUNOLOGY & AUTOIMMUNE DISEASES

<u>Parameter</u>	<u>CAP</u>	<u>INSTAND</u>	<u>LABQUALITY</u>	<u>SEKK</u>	<u>SZÚ</u>
Antibodies to Saccharomyces cerevisiae (ASCA)				100.0%	
Cyclic citrullinated peptides (CCP)		100.0%		100.0%	
Deamidated gliadin (Gliadin DA)		100.0%	100.0%	100.0%	
Double-stranded DNA (dsDNA)*		100.0%			
Jo-1	100.0%				
Rheumatoid Factor (RF)		100.0%		100.0%	
Scl-70	100.0%				
Transglutaminase (TA)		100.0%	100.0%	100.0%	

*This parameter was not tested in EQA in Q3-Q4 2025. Therefore, the latest available results are reported to ensure that all products evaluated in EQA are represented in the document.

Infectious Diseases

Bordetella

INSTAND – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive	positive	+
IgA	negative	negative	+
IgG	positive	positive	+
IgG	negative	negative	+
IgM	borderline, negative	negative	+
IgM	negative	negative	+
Interpretation	acute infection	acute infection	+
Interpretation	no evidence of infection	no evidence of infection	+

LABQUALITY – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive	positive	+
IgA	negative	negative	+
IgG	positive	positive	+
IgG	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
Interpretation	infection confirmed	infection confirmed	+
Interpretation	no evidence of infection	no evidence of infection	+

Borrelia

INSTAND – 06.2025

The Antibody Index Software was not tested in EQA in Q3-Q4 2025. Therefore, the results from Q2 are reported so that all products evaluated in EQA are represented in the document.



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
AI SW (IgG)	negative	negative	+

LABQUALITY – 09.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	positive	positive	+
IgM	positive	positive	+
IgM	positive	positive	+
Interpretation	infection confirmed	infection confirmed	+
Interpretation	infection confirmed	infection confirmed	+

INSTAND – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	negative	negative	+
IgM	positive, borderline, negative	negative	+
IgM	negative	negative	+
Interpretation	late infection	late infection	+
Interpretation	no evidence of infection	no evidence of infection	+

SZÚ – 12.2025




<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

Chlamydia

LABQUALITY – 07.2025

Chlamydia pneumoniae




<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA*	the sample was not evaluated		
IgA	negative	positive	-
IgA	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgG	negative	positive	-
IgM	negative	negative	+
IgM	positive	positive	+
IgM	negative	negative	+
Interpretation	late infection	acute infection	-
Interpretation	acute infection	acute infection	+
Interpretation	no evidence of infection	late infection	-

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.


SZÚ – 08.2025

Chlamydia



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	negative	negative	+
IgA	negative	positive	-
IgA	negative	negative	+
IgA	negative	negative	+
IgA	negative	negative	+
IgG	negative	negative	+
IgG	positive	positive	+
IgG	negative	negative	+
IgG	negative	negative	+
IgG	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

Chlamydia pneumoniae



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	negative	negative	+
IgA	positive	positive	+
IgA	negative	negative	+
IgA	negative	positive	-
IgA	negative	positive	-
IgG	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

Chlamydia trachomatis



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	negative	negative	+
IgA	positive	positive	+
IgA	negative	negative	+
IgA	negative	negative	+
IgA	negative	negative	+
IgG	negative	negative	+
IgG	positive	positive	+
IgG	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

INSTAND – 11.2025

Chlamydia pneumoniae



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive, borderline, negative	positive	+
IgA	negative	negative	+
IgG	positive	positive	+
IgG	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
Interpretation	acute, late infection	acute infection	+
Interpretation	no evidence of infection	no evidence of infection	+

Chlamydia trachomatis



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive, borderline, negative	negative	+
IgA	negative	negative	+
IgG	borderline, positive	positive	+
IgG	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
Interpretation	acute, late infection	acute infection	+
Interpretation	no evidence of infection	no evidence of infection	+

LABQUALITY – 12.2025

Chlamydia pneumoniae



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive	positive	+
IgA	positive	positive	+
IgA	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM*	the sample was not evaluated		
IgM	negative	negative	+
IgM	negative	negative	+

Clinical evaluation



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Interpretation*	the sample was not evaluated		
Interpretation*	the sample was not evaluated		
Interpretation	late infection	late infection	+

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

Coronavirus (COVID-19)

INSTAND – 12.2025

COVID-19 NP



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA*	the sample was not evaluated		
IgA*	the sample was not evaluated		
IgA*	the sample was not evaluated		
IgA*	the sample was not evaluated		
IgG	negative	negative	+
IgG	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM*	the sample was not evaluated		
IgM*	the sample was not evaluated		
IgM*	the sample was not evaluated		
IgM*	the sample was not evaluated		

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

COVID-19 RBD



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA*		the sample was not evaluated	
IgA*		the sample was not evaluated	
IgA*		the sample was not evaluated	
IgA*		the sample was not evaluated	
IgG	positive	positive	+
IgG	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM*		the sample was not evaluated	
IgM*		the sample was not evaluated	
IgM*		the sample was not evaluated	
IgM*		the sample was not evaluated	

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

Cytomegalovirus (CMV)

INSTAND – 07.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high (50-100%)	high (98%)	+
IgG	negative	negative	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+

LABQUALITY – 09.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high	high	+
Avidity	low	low	+
IgG	positive	positive	+
IgG	negative	positive	+
IgG	positive	positive	+
IgM	negative	positive	+
IgM	negative	negative	+
IgM	positive	positive	+
Interpretation	late infection	late infection	+
Interpretation	no evidence of infection	no evidence of infection	+
Interpretation	acute infection	acute infection	+

CAP – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+
IgG	negative	negative	+

Epstein-Barr virus (EBV)

INSTAND – 07.2025

EBV EBNA EA-D



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG*	the sample was not evaluated		
IgG*	the sample was not evaluated		
IgM*	the sample was not evaluated		
IgM*	the sample was not evaluated		

EBV EBNA-1



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

EBV VCA



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high (50-100%)	high (101%)	+
Avidity	high (50-100%)	high (102%)	+
IgA*	the sample was not evaluated		
IgA*	the sample was not evaluated		
IgG	positive	positive	+
IgG	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

Clinical evaluation



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Interpretation	late infection	late infection	+
Interpretation	late infection	late infection	+

LABQUALITY – 10.2025

EBV EBNA



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+
IgG	negative	negative	+
IgM	positive	positive	+

EBV VCA



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	low	low (22%)	+
Avidity	high	high (85%)	+
IgG	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	positive	negative	-
IgM	negative	negative	+

Clinical evaluation



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Interpretation	no evidence of infection	no evidence of infection	+
Interpretation	acute infection	acute infection	+
Interpretation	late infection	late infection	+

CAP – 12.2025

EBV EA-D



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG*	the sample was not evaluated		

EBV EBNA-1



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG*	the sample was not evaluated		
IgM*	the sample was not evaluated		

EBV VCA



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG*	the sample was not evaluated		
IgM*	the sample was not evaluated		

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

INSTAND – 12.2025

EBV EBNA EA-D



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG*		the sample was not evaluated	
IgG*		the sample was not evaluated	
IgM*		the sample was not evaluated	
IgM*		the sample was not evaluated	

EBV EBNA-1



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+
IgG	positive	positive	+
IgM	positive	positive	+
IgM	negative	negative	+

EBV VCA



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	low	low (9%)	+
Avidity	high	high (93%)	+
IgA*		the sample was not evaluated	
IgA*		the sample was not evaluated	
IgG*		the sample was not evaluated	
IgG	positive	positive	+
IgM	positive	negative	+
IgM	negative	negative	+

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

Clinical evaluation



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Interpretation	acute infection	acute infection	+
Interpretation	late infection	late infection	+

Helicobacter

SZÚ – 08.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive	positive	+
IgA	negative	negative	+
IgA	negative	negative	+
IgA	negative	negative	+
IgG	positive	positive	+
IgG	negative	negative	+
IgG	negative	negative	+
IgG	negative	negative	+

LABQUALITY – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	positive	positive	+
IgM	positive	positive	+
IgM	positive	positive	+
Interpretation	infection confirmed	infection confirmed	+
Interpretation	infection confirmed	infection confirmed	+

INSTAND – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive, borderline, negative	negative	+
IgA	positive, borderline, negative	negative	+
IgG	negative	negative	+
IgG	positive	positive	+
Interpretation	no evidence of infection	no evidence of infection	+
Interpretation	infection confirmed	infection confirmed	+

CAP – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA*	the sample was not evaluated		
IgG	positive	positive	+

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

Herpes simplex virus (HSV)

SZÚ – 08.2025

HSV




<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+

HSV 1



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+

HSV 2



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+
IgG	positive	negative	-
IgM	negative	negative	+
IgM	negative	negative	+


LABQUALITY – 09.2025

HSV



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	negative	negative	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

HSV 1



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG*	the sample was not evaluated		
IgG	negative	positive	-
IgG	negative	negative	+

HSV 2



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	negative	negative	+
IgG	positive	positive	+

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

CAP – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+

INSTAND – 12.2025

HSV




<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high (50-100%)	high (84%)	+
Avidity	high (50-100%)	high (82%)	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+

HSV 1



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+

HSV 2



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	borderline	-
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+

Measles

INSTAND – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high (50-100%)	high (70%)	+
IgG	positive	positive	+
IgG	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

Mumps

INSTAND – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM*	the sample was not evaluated		

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

Mycoplasma

INSTAND – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	negative	negative	+
IgA	positive, borderline, negative	negative	+
IgG	positive, borderline	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	positive, borderline, negative	positive	+
Interpretation	no evidence of infection	no evidence of infection	+
Interpretation	acute, late infection	acute infection	+

LABQUALITY – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG*	the sample was not evaluated		
IgM	negative	negative	+
IgM	positive	positive	+
Interpretation	late infection	late infection	+
Interpretation	acute infection	acute infection	+

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

CAP – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG*		the sample was not evaluated	
IgM*		the sample was not evaluated	

Parvovirus B19

INSTAND – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

Rubella

CAP – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+

INSTAND – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high (50-100%)	high (90%)	+
Avidity	high (50-100%)	high (87%)	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+

Tick-Borne Encephalitis Virus (TBEV)

INSTAND – 07.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high	high (78%)	+
Avidity	high	high (69%)	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+

SZÚ – 09.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high	high	+
Avidity	high	high	+
Avidity	high, medium	medium	+
IgG	positive	positive	+
IgG	positive	positive	+
IgG	negative	negative	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

Tetanus

INSTAND – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	positive	positive	+
Interpretation	infection confirmed	infection confirmed	+
Interpretation	infection confirmed	infection confirmed	+

Toxocara

SZÚ – 01.2025

This parameter was not tested in EQA in Q3–Q4 2025. Therefore, the results from Q1 are reported so that all products evaluated in EQA are represented in the document.



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgG	negative	negative	+
IgG	negative	negative	+
IgG	positive	positive	+
IgG	negative	negative	+

Toxoplasma

LABQUALITY – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high	high	+
Avidity	high	high	+
IgG	positive	positive	+
IgG	positive	positive	+
IgG	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
Interpretation	late infection	late infection	+
Interpretation	late infection	late infection	+
Interpretation	no evidence of infection	no evidence of infection	+

CAP – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+
IgM	negative	negative	+

SZÚ – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high	high	+
Avidity	high	high	+
IgA	negative	negative	+
IgA	negative	negative	+
IgA	negative	negative	+
IgA	negative	negative	+
IgA	negative	negative	+
IgE	negative	negative	+
IgE	negative	negative	+
IgE	negative	negative	+
IgE	negative	negative	+
IgE	negative	negative	+
IgG	negative	negative	+
IgG	negative	negative	+
IgG	negative	negative	+
IgG	negative	negative	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

Treponema

SZÚ – 07.2025

Treponema pallidum TOTAL



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Total	negative	negative	+
Total	positive	positive	+
Total	positive	positive	+
Total	positive	positive	+
Total	positive	positive	+

Treponema pallidum



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+
IgG	positive	positive	+
IgG	positive	positive	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	positive	positive	+
IgM	positive	positive	+
IgM	positive	positive	+
IgM	negative	negative	+

Varicella zoster virus (VZV)

INSTAND – 07.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high (50-100%)	high (74%)	+
Avidity	high (50-100%)	high (91%)	+
IgG	positive	positive	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	negative	negative	+

SZÚ – 08.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Avidity	high	high	+
IgG	positive	positive	+
IgG	negative	negative	+
IgM	negative	negative	+
IgM	negative	negative	+

CAP – 12.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive	+

Yersinia

SZÚ – 07.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive	positive	+
IgA	negative	negative	+
IgG	positive	positive	+
IgG	negative	negative	+
IgM	positive	positive	+
IgM	negative	negative	+

Immunology & Autoimmune Diseases

Antibodies to *Saccharomyces cerevisiae* (ASCA)

SEKK – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive	positive	+
IgA	negative	negative	+
IgG	positive	positive	+
IgG	negative	negative	+

Cyclic citrullinated peptides (CCP)

INSTAND – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	positive	positive (high)	+
IgG	positive	positive (high)	+

SEKK – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+
IgG	positive	positive	+

Deamidated gliadin (Gliadin DA)

INSTAND – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	borderline, positive	borderline	+
IgA	borderline, positive	positive (low)	+
IgG	borderline, positive	positive (medium)	+
IgG	borderline, positive	positive (high)	+

SEKK – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	negative	negative	+
IgA	positive	positive	+
IgG	negative	negative	+
IgG	positive	positive	+

LABQUALITY – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA*	the sample was not evaluated		
IgA	negative	negative	+
IgG*	the sample was not evaluated		
IgG	positive	positive	+

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

Double-stranded DNA (dsDNA)

INSTAND – 04.2025

This parameter was not tested in EQA in Q3-Q4 2025. Therefore, the results from Q2 are reported so that all products evaluated in EQA are represented in the document.



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
Anti-dsDNA	positive, negative	negative	+
Anti-dsDNA*	the sample was not evaluated		

* The results for this sample were ambiguous (due to plasma pooling causing sample inhomogeneity, mixture of antigens in kits etc.) – therefore this sample was not included in the final evaluation of any manufacturer.

Jo-1

CAP – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+

Rheumatoid Factor (RF)

INSTAND – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive	positive (high)	+
IgA	negative	negative	+
IgG	borderline, positive	positive (low)	+
IgG	negative	negative	+
IgM	positive	positive (high)	+
IgM	negative	negative	+

SEKK – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	negative	negative	+
IgA	positive	positive	+
IgG	negative	negative	+
IgG	positive	positive	+
IgM	negative	negative	+
IgM	positive	positive	+

Sci-70

CAP – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgG	negative	negative	+

Transglutaminase (TA)

INSTAND – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive	positive (high)	+
IgA	positive	positive (medium)	+

SEKK – 10.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	negative	negative	+
IgA	positive	positive	+

LABQUALITY – 11.2025



<u>Category</u>	<u>Sample specification</u>	<u>TestLine result</u>	<u>Meets criteria</u>
IgA	positive	positive	+
IgA	negative	negative	+
IgG	negative	negative	+
IgG	positive	positive	+